Roche Widens Serology Portfolio with New Elecsys® Syphilis Test

25 Apr 2014
Share
Roche is pleased to announce the launch of the Elecsys® Syphilis test. The new Elecsys assay enables the detection of total antibodies to T. pallidum (detection of IgG & IgM antibodies against TpN15, TpN17 & TpN47) and complements the Mediace® Rapid Plasma Reagin (RPR) and T. pallidum Latex Agglutination® (TPLA) Roche assays, allowing reliable detection of infection and treatment monitoring for syphilis.

The Elecsys Syphilis assay demonstrates 100% sensitivity and 99.88% specificity with perfect discrimination of results eliminating the need for a grey zone and delivering confidence in all stages of treponemal infection.

For over 25 years Roche has invested in the research and development of serology analysers and assays so that, today, it offers one of the most comprehensive infectious diseases assay portfolios available on a single automated platform.

For more information please click on the ‘request information’ tab below or follow the company website link.

Photograph caption: Roche has launched the Elecsys Syphilis assay for the reliable detection of Syphilis infection and treatment monitoring.

Request Info


Company website

Tags: syphilis

Roche Diagnostics UK
profile photo

Sonia Nicholas
Clinical Diagnostics Editor